AGP Executive Report
Last update: 4 hours agoFDA Approvals: The FDA cleared Revolution Medicines’ Rasonque (daraxonrasib) as the first RAS-directed therapy for previously treated metastatic pancreatic cancer, after a phase 3 trial showed longer survival than standard chemo. The agency also expanded HIV care for kids, approving Tivicay PD (dolutegravir) for pediatric patients weighing at least 2 kg, and approved Tevimbra plus Ziihera with chemotherapy for first-line HER2+ gastric/gastroesophageal/esophageal adenocarcinoma. Cancer Diagnostics & Care Pathways: A European pilot study found AI-assisted nodule detection plus a navigator-tracked follow-up clinic helped catch early lung cancer from incidental CT findings. Healthcare Policy & Costs: The AHA urged CMS not to finalize outpatient payment changes that would accelerate 340B clawbacks and strain hospitals. A separate report says the Trump administration is preparing another round of Medicaid drug-pricing deals tied to “Most Favored Nation” discounts. Practice Operations & Regulation: STAT reports practice management deal volume is down sharply in 2026 amid tighter state oversight. Cybersecurity: Boston Scientific disclosed a cybersecurity incident disrupting IT systems and order processing. Behavioral Health Innovation: Onos Health raised $17M to expand an AI platform for behavioral health care pattern and gap analysis.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[What Executives and Investors Are Looking for in Pharma Companies]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/27870198-937222876-8f4ab05110c2c708f312059c0cfda3018f10b118-1280x720-200x113.jpeg)
![<![CDATA[What Executives and Investors Are Looking for in Pharma Companies]]>](/images/news-fallback.svg)
